CRISPR/Cas9 gene editing therapy (Agenovir)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCRISPR/Cas9 gene editing therapy (Agenovir)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAgenovir Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAgenovir Corp
Active IndicationsN/A
Inactive IndicationsPapillomavirus Infections

Other Information

ATC CodeN/A
Related LinksN/A